1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Neurturin (NRTN), a member of the glial-derived neurotrophic factor family, was identified from an embryonic chicken pancreatic cDNA library in a screen for secreted factors. In this study, we assessed the potential antidiabetic activities of NRTN relative to liraglutide, a glucagon-like peptide 1 receptor agonist, in Zucker diabetic fatty (ZDF) rats. Subcutaneous administration of NRTN to 8-week-old male ZDF rats prevented the development of hyperglycemia and improved metabolic parameters similar to liraglutide. NRTN treatment increased pancreatic insulin content and β-cell mass and prevented deterioration of islet organization. However, unlike liraglutide-treated rats, NRTN-mediated improvements were not associated with reduced body weight or food intake. Acute NRTN treatment did not activate c-Fos expression in key feeding behavior and metabolic centers in ZDF rat brain or directly enhance glucose-stimulated insulin secretion from pancreatic β-cells. Treating 10-week-old ZDF rats with sustained hyperglycemia with liraglutide resulted in some alleviation of hyperglycemia, whereas NRTN was not as effective despite improving plasma lipids and fasting glucose levels. Interestingly, coadministration of NRTN and liraglutide normalized hyperglycemia and other metabolic parameters, demonstrating that combining therapies with distinct mechanism(s) can alleviate advanced diabetes. This emphasizes that therapeutic combinations can be more effective to manage diabetes in individuals with uncontrolled hyperglycemia.

          Related collections

          Author and article information

          Journal
          Diabetes
          Diabetes
          American Diabetes Association
          1939-327X
          0012-1797
          July 2017
          : 66
          : 7
          Affiliations
          [1 ] Department of Cardiovascular and Metabolic Diseases, MedImmune LLC, Gaithersburg, MD trevaskisj@medimmune.com.
          [2 ] Department of Cardiovascular and Metabolic Diseases, MedImmune LLC, Gaithersburg, MD.
          [3 ] Translational Sciences (Pathology), MedImmune LLC, Gaithersburg, MD.
          [4 ] Biopharmaceutical Development, MedImmune LLC, Gaithersburg, MD.
          [5 ] Statistical Sciences, MedImmune LLC, Gaithersburg, MD.
          [6 ] Evotec, Göttingen, Germany.
          [7 ] CVMD Innovative Medicines Unit, AstraZeneca, Molndal, Sweden.
          [8 ] Discovery Sciences, Innovative Medicines & Early Development Biotech Unit, AstraZeneca, Cambridge, U.K.
          [9 ] Gubra, Horsholm, Denmark.
          [10 ] Research Project and Portfolio Management, MedImmune Ltd., Cambridge, U.K.
          [11 ] Department of Cardiovascular and Metabolic Diseases, MedImmune Ltd., Cambridge, U.K.
          Article
          db16-0916
          10.2337/db16-0916
          28408435

          Comments

          Comment on this article